Navigation Links
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
Date:12/3/2008

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008, at 4:00 p.m. PST, to discuss the results of Rigel's Phase 2 clinical trial of R788, an oral Syk kinase inhibitor, in patients with B-cell non-Hodgkin's lymphomas.

Conference Call and Webcast Information

To access the live call, please dial 800-561-2693 (domestic) or 617-614-3523 (international) 10 minutes prior to the start time and use the passcode 36883961. A replay of the call will be available, in webcast and podcast formats, at approximately 6:00 p.m. PST on December 7, 2008 through December 14, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 47095093. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

In addition, Rigel will be participating in a plenary session during the 50th Annual American Society of Hematology (ASH) Meeting in San Francisco, California from December 6-9, 2008.

ASH Presentation Details

Plenary session: Sunday, December 7, 2008 - 2:40 p.m. PST

Title: 3 - Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphoctytic Leukemia (SLL/CLL)

Location: Halls B and C (Moscone Center)

About Rigel ('/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Host Update Conference Call
4. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
5. Rigel to Present at BIO CEO & Investor Conference
6. Rigel Announces Pricing of Public Offering of Common Stock
7. Rigel to Present Research Programs at Scientific Conferences
8. Rigel to Present at BIO Investor Forum 2007
9. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
10. Medarex to Present at the RBC Capital Markets Healthcare Conference
11. Bionovo to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...uly 2 Advanced Chemical Transport...alifornia, has announced a multi-year partnership ...argest Bio-Med company. , , ACT will provide En...ls disposal, vacuum truck services, spill response...nt support from its corporate headquarters in Sunn...
(Date:7/2/2009)...ewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:...t enrolment has been completed in the Phase II com...ined with paclitaxel/carboplatin for patients with... the trial are Dr. Kevin Harrington of The Institu...off Hall of St. James,s Institute of Oncology, Lee...
(Date:7/1/2009)... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc...ved an award from BASF for,excellent service and ...ynthesis for new crop-protection active ingredient.../prnh/20040705/CNM002LOGO ) , "We had been...years, and,today I think we have found one, a top...
(Date:7/1/2009)...RNewswire/ -- Biocept, Inc. ("Biocept"), an emergi...pointment of Daniel H. Petree and M. Faye Wilson a...n and Faye to our Board. Their experience will be ... development," said Stephen M. Coutts, President a... Wilson Boyles and Company, a business management ...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial 2WuXi PharmaTech Receives Award from BASF 2Biocept, Inc. Announces Two New Director Appointments 2
... At one level, its possible to understand why ani...ts involving animals. No one likes to see another ... however, exist facts about animal-based research ...me protesters, such as those who recently targeted...about the true extent of animal research and its ...
...e of a two part article. The next installment cov...es to take will appear next week. , , You or yo...tle perceived need to be concerned with patent mat...s that consider enforcing patents to be a main or ...ore and more businesses have to be concerned with ...
... Software , a Merge Healthcare developer of medi...ic partnership with Ft. Lauderdale-based dental im...terms of the partnership agreement, Cedara will be...mplant technology. Cedara will use its industry co...stomers worldwide. Cedara will also contribute to ...
...ckage of legislative incentives proposed recently ...ts to transform Wisconsins economy into a knowledg...ls, dubbed Invest Wisconsin, seeks to encourage th...part of a three- to four-year campaign designed to...eform, workforce retraining, infrastructure enhanc...
Other Biology Technology:Animal testing: Beyond the protests, instances of mistreatment are rare 2Animal testing: Beyond the protests, instances of mistreatment are rare 3Patent enforcement: What you don't know might hurt you 2Patent enforcement: What you don't know might hurt you 3Patent enforcement: What you don't know might hurt you 4Republicans propose sweeping changes to promote investment 2Republicans propose sweeping changes to promote investment 3Republicans propose sweeping changes to promote investment 4
(Date:7/2/2009)... celebrates its birth on the 4th of July, Universi... Caribbean coral reef nursery scientists will be c...spheric Administration (NOAA) today announced that... and elkhorn coral recovery project, including Lir...ive support from the American Recovery and Reinves...
(Date:7/1/2009)...e European Molecular Biology Laboratory,s European... a major new e-science resource for biologists wh...H1N1 flu and cancer. , Biocatalogue.org , a cen...ices, is being officially launched today (Wednesda...nce on Intelligent Systems for Molecular Biology a...
(Date:7/1/2009)...ciation has released an updated position paper on ...l-planned, are healthful and nutritious for adults...revent and treat chronic diseases including heart ...osition, published in the July issue of the Journ...ts the Association,s official stance on vegetarian...
(Date:7/1/2009)...gest study to date of endometriosis in pregnant wo...actor for premature birth, the 25th annual confere...and Embryology heard today (Wednesday July 1). Dr....hild Health, Karolinska Institute, Stockholm, Swed...ndometriosis also had a higher risk of other pregn...
Breaking Biology News(10 mins):Nursery programs for corals receive TLC from NOAA this Independence Day 2New e-science service could accelerate cancer research 2ADA releases updated position paper on vegetarian diets 2Women with endometriosis need special care during pregnancy to avoid risk of premature birth 2Flu Shots Worthwhile for College Students 31477 1Flu Shots Worthwhile for College Students 31477 2Alfacell Provides ONCONASE 28R 29 NDA Submission Update 3550 1Alfacell Provides ONCONASE 28R 29 NDA Submission Update 3550 2Alfacell Provides ONCONASE 28R 29 NDA Submission Update 3550 3Alfacell Provides ONCONASE 28R 29 NDA Submission Update 3550 4Yourway Transport Expands 9531 1Yourway Transport Expands 9531 2FRC 3A New Mental Health Studies Dispel Myth That Abortion Is A Non Event 31471 1
... a way to transform the dead bone of a transplante...nt involving mice. The advance, which uses gene th...ign splint as living bone, is a promising developm...s each year who suffer with fragile and failing bo... and will appear in the March 1 issue of Nature Me...
...ued Patent # 6,872,552, "A Method of Reconstitutin... Ph.D, Chairman of MatrixDesign, and CEO of DermaP... and reconstituting genes from "degraded" DNA samp...ything from prehistoric, extinct animals to unsolv...applied by our scientists, brings us closer to our...
...al conducted by Optobionics Corporation involving ...d Emory Eye Center and the Atlanta Veterans Affair... to implant the device in several patients. The pa...-to-severe vision loss. Three centers in the Unite...trial. Other than Emory and the VA Rehabilitation ...
...proteins have been,viewed as the real movers and s... more than a messenger that shuttles information b...titute for Biomedical Research,and Massachusetts I...RNA molecules called microRNAs regulate thousands ...s protein-coding regions. In other words,a class ...
Other Biology News:Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4Dinosaur DNA? New Patent Covers Degraded DNA recovery 2Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa 2Study finds more than one-third of human genome regulated by RNA 2
...e derived from frozen embedded tissue blocks, whic...ures to ensure the highest quality. Tissues of eac...oned at a thickness of 7 microns and mounted on co...r) in comparison to core sections made using Tissu...
...is a completely redesigned and updated version of ...ll line of well-proven Alpha heat-pump assemblies....ance as the DNA Engine Dyad, and original Tetrad t...ls among platforms. The Tetrad 2 contains an onboa...
...ptors, 24 glass tubes (1.5 mm ID, 180 mm length), ...l and PROTEAN II XL wide-format cell offer the ver...luding SDS-PAGE, first- and second-dimension 2-D e...PAGE as well as high-resolution agarose electropho...
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system.
Biology Products: